人甲状腺细胞中血管活性肠肽能受体与胆碱能受体的相互作用。

Interaction of VIPergic and cholinergic receptors in human thyroid cell.

作者信息

Brandi M L, Tanini A, Toccafondi R

机构信息

Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892.

出版信息

Peptides. 1987 Sep-Oct;8(5):893-7. doi: 10.1016/0196-9781(87)90077-5.

DOI:10.1016/0196-9781(87)90077-5

PMID:2829144

Abstract

The thyroid tissue is innervated by cholinergic and VIPergic nerves. The present study investigated the possible interactions of cholinergic agents with VIP-induced cAMP accumulation and thyroid hormone release in vitro. Carbamylcholine (Cch), acting through the muscarinic receptor increases cellular cGMP content in cultured human thyroid cells incubated with a phosphodiesterase inhibitor. Cch (10 microM) inhibits cellular cAMP accumulation and thyroxine (T4) release induced by vasoactive intestinal peptide (VIP), with or without a phosphodiesterase inhibitor. Cch (10 microM) inhibits 8-bromo-cAMP-induced T4 release from human thyroid slices. 8-Bromo-cGMP inhibits VIP-induced T4 release from human thyroid slices, only in cells incubated without the phosphodiesterase inhibitor. The results indicate that interactions between VIPergic and cholinergic receptors may be of importance in human thyroid cell.

摘要

甲状腺组织受胆碱能神经和血管活性肠肽能神经支配。本研究调查了胆碱能药物与血管活性肠肽诱导的环磷酸腺苷（cAMP）积累及甲状腺激素体外释放之间可能存在的相互作用。氨甲酰胆碱（Cch）通过毒蕈碱受体发挥作用，可增加与磷酸二酯酶抑制剂一起孵育的培养人甲状腺细胞中的细胞内环磷酸鸟苷（cGMP）含量。无论有无磷酸二酯酶抑制剂，Cch（10微摩尔）均可抑制血管活性肠肽（VIP）诱导的细胞内cAMP积累及甲状腺素（T4）释放。Cch（10微摩尔）可抑制8-溴-cAMP诱导的人甲状腺切片中T4的释放。仅在未与磷酸二酯酶抑制剂一起孵育的细胞中，8-溴-cGMP可抑制人甲状腺切片中VIP诱导的T4释放。结果表明，血管活性肠肽能受体与胆碱能受体之间的相互作用在人甲状腺细胞中可能具有重要意义。